Subcutaneous apomorphine-induced pneumonitis: An uncommon pulmonary adverse event
Respiratory Medicine Case Reports · 2026 · 62 · 102446
DOI: 10.1016/j.rmcr.2026.102446 ↗Kurz gefasst
Fallbericht in der Zeitschrift Respiratory Medicine Case Reports, 2026. Verfasst von Enrique Barrueco-Otero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Outpatient follow-up, Primary Care Service, University Hospital of Salamanca, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Apomorphine is a potent dopaminergic agonist widely used in the management of motor fluctuations in advanced Parkinson's disease. Although generally well tolerated, rare pulmonary adverse drug reactions (ADRs) may occur. We report a case of probable apomorphine-induced pneumonitis associated with subcutaneous administration. Case presentation: A 62-year-old Caucasian male with multiple comorbidities presented to the emergency department with headache, non-productive cough, central chest pain, fever, and dyspnea over the past 48 hours (3 weeks after initiation of subcutaneous apomorphin). Chest X-ray revealed bilateral hilar infiltrates and basal consolidation. CT scan showed organizing pneumonia (OP)-like pattern. Extensive microbiological evaluation of bronchoalveolar lavage and bronchial aspirate samples, including bacterial, fungal, mycobacterial, viral, and atypical pathogen testing, was negative. Lack of response to broad-spectrum antibiotics raised the suspicion of drug-induced pneumonitis due to subcutaneous apomorphine. Antibiotics were discontinued, and corticosteroid therapy (methylprednisolone 40 mg/day) was initiated with gradual tapering resulted in rapid clinical improvement and complete radiological resolution within one month.
Conclusion
The temporal relationship between apomorphine initiation and symptom onset, compatible clinical and radiological findings, extensive microbiological exclusion of infectious causes, and favorable response after drug withdrawal and corticosteroid therapy supported the diagnosis of probable apomorphine-induced pneumonitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Outpatient follow-up, Primary Care Service, University Hospital of Salamanca, Spain.
- Pulmonology Service, University Hospital of Salamanca, Spain.
- Internal Medicine Service, University Hospital of Salamanca, Spain.
- University Hospital of Salamanca and Department of Medicine, University of Salamanca (USAL), Spain.
- Pulmonology Service, University Hospital of Salamanca and Department of Medicine, University of Salamanca (USAL), Spain.
Zitieren
APA
Barrueco-Otero, E., Hidalgo-Sierra, V., Piñero, P. T., Fernández, I. G., Pintor, L. G., Sánchez, M. B., Corbi Cobo-Losey, M. J., Montilla, C., & Hernández-Mezquita, M. Á. (2026). Subcutaneous apomorphine-induced pneumonitis: An uncommon pulmonary adverse event. Respiratory Medicine Case Reports, 62, 102446. https://doi.org/10.1016/j.rmcr.2026.102446
Vancouver
Barrueco-Otero E, Hidalgo-Sierra V, Piñero PT, Fernández IG, Pintor LG, Sánchez MB, et al. Subcutaneous apomorphine-induced pneumonitis: An uncommon pulmonary adverse event. Respiratory Medicine Case Reports. 2026;62:102446. doi:10.1016/j.rmcr.2026.102446
BibTeX
@article{BarruecoOtero2026,
author = {Barrueco-Otero, Enrique and Hidalgo-Sierra, Vanesa and Piñero, Patricia Torres and Fernández, Isabel González and Pintor, Laura Gil and Sánchez, María Bartol and Corbi Cobo-Losey, María Jesús and Montilla, Carlos and Hernández-Mezquita, Miguel Ángel},
title = {Subcutaneous apomorphine-induced pneumonitis: An uncommon pulmonary adverse event},
journal = {Respiratory Medicine Case Reports},
year = {2026},
volume = {62},
pages = {102446},
doi = {10.1016/j.rmcr.2026.102446}
}
EUVIMED